个人简介

2009年毕业于山东大学，获理学学士；2015年毕业于中国科学院上海巴斯德研究所李斌研究员实验室，获理学博士。博士阶段主要鉴定了一系列靶向自身免疫病、炎症、肿瘤等疾病状态下致病蛋白的促降解新靶点DUB/E3并深入探索阐明了作用机制。 2015年-2020年底在美国哈佛大学医学院Dana-Farber癌症研究所Sara J. Buhrlage和 James D. Griffin 教授实验室进行博士后训练，2021年1月-2022年8月在中国科学院合肥研究院任副研究员，开展了多种恶性血液肿瘤的治疗型新靶点DUB/E3 发现和首创型降解剂研发。期间入选主持国家自然科学基金，中国科学院青年创新促进会会员和安徽省 青年项目等，并参与美国国立卫生研究院NIH等多项国家项目。 2022年9月加盟同济大学生命科学与技术学院，入选上海市“海外高层次人才引进计划”，任特聘研究员，博士生导师。2023年1月至今兼任上海市同济医院研究员。部分成果以第一或通讯（含共同）作者在Nat. Chem. Biol.，Leukemia（2022a，2022b），Signal Trans. Target. Ther.，EMBO Rep.，Br. J. Cancer等重要学术期刊发表研究论文12篇，受 Nat. Rev. Drug Discov. Nat. Immunol., Blood等著名期刊,专刊或亮点点评，成果转化已申请多项专利。受邀参编英文专著一部（ISSN 2213-2775），担任Cancers、Front. Microbiol.、Biomedicines等国际期刊审稿人，中国细胞生物学学会会员等，并多次在国际国内学术会议做大会及分会报告。

研究领域

研究组致力于白血病等恶性疾病的靶向和免疫治疗相关促降解新靶点发现和首创型靶向降解剂研发，目前主要研究方向包括： 1. 白血病等恶性疾病中致病蛋白促降解新靶点去泛素化酶 (DUB) 和泛素化酶（E3）及其配体的发现 2. 克服多种耐药、突变选择型治疗新靶点及药物的发现 3. 免疫治疗新靶点、小分子免疫调节剂和肿瘤免疫联合疗法的开发

蛋白降解新靶点与药物

近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Yiying Xue#, Husheng Mei#, Yisa Chen, James D. Griffin, Qingsong Liu*, Ellen Weisberg*, Jing Yang*. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-COV-2. MedComm. May 2023; 4(3):e254. Yisa Chen, Yiying Xue, Jing Yang*. Gilteritinib: Repurposing of AXL-targeting kinase inhibitors against COVID-19. Journal of Medical Virology, Mar. 2023; 95(3):e28592. Husheng Mei#, Hong Wu#, Jing Yang#, Bin Zhou#, Aoli Wang, Chen Hu, Shuang Qi, Zongru Jiang, Fengming Zou, Beilei Wang, Feiyang Liu, Yongfei Chen, Zuowei Wang, Wenchao Wang*, Jing Liu*, Qingsong Liu*. Discovery of IHMT-337 as a potent irreversible inhibitor targeting novel noncanonical role of EZH2 for triple-negative breast cancer. Signal Transduct. Target Ther., 8 (1), 18, Jan. 2023. Jing Yang#, Ellen L. Weisberg#, Shuang Qi#, Wei Ni, Husheng Mei, Zuowei Wang, Chengcheng Meng, Shengzhe Zhang, Mingqi Hou, Ziping Qi, Aoli Wang, Yunyun Jiang, Zongru Jiang, Tao Huang, Qingwang Liu, Robert S. Magin, Laura Doherty, Wenchao Wang, Jing Liu, Sara J. Buhrlage*, Qingsong Liu*, James D. Griffin*. Inhibition of deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia. 36, pages 1048-1057, Apr. 2022 Jing Yang#, Ellen L. Weisberg#, Xiaoxi Liu#, Robert Magin, Wai Cheung Chan, Bin Hu, Nathan Schauer, Shengzhe Zhang, Ilaria Lamberto, Laura Doherty, Chengcheng Meng, Martin Sattler, Lucia Cabal-Hierro, Eric Winer, Richard Stone, Jarrod Marto, James Griffin*, Sara Buhrlage*. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia. 36, pages 210–220. Jan. 2022 Jing Yang#, Ping Wei#, Joseph Barbi, Qianru Huang, Evan Yang, Yakun Bai, Jia Nie, Yanhang Gao, Jinhui Tao, Ying Lu, Chichu Xie, Xiaoxia Hou, Jiazi Ren, Xingmei Wu, Jian Meng, Ying Zhang, Juan Fu, Wei Kou, Yayi Gao, Zuojia Chen, Rui Liang, Andy Tsun, Dan Li, Wenzhi Guo, Shuijun Zhang, Song-Guo Zheng, Junqi Niu, Paul Galardy, Xuemei Tong, Guochao Shi, Huabin Li*, Fan Pan* and Bin Li*. The deubiquitinase USP44 promotes Treg function during inflammation by preventing FOXP3 degradation. EMBO Reports. 21 (9), e50308 Jul. 2020 Jing Yang#, Chengcheng Meng#, Ellen L. Weisberg#, Ilaria Lamberto, Martin Sattler, Nathanael S. Gray, Sara J. Buhrlage*, James D. Griffin*. Inhibition of the deubiquitinase USP10 induces degradation of SYK. British Journal of Cancer, 122 (8), 1175-1184. Feb. 2020 Ellen L. Weisberg#, Nathan J. Schauer#, Jing Yang#, Ilaria Lamberto#, Laura Doherty, Shruti Bhatt, Atsushi Nonami, Chengcheng Meng, Anthony Letai, Renee Wright, Hong Tiv, Prafulla C. Gokhale, Maria Stella Ritorto, Virginia De Cesar, Matthias Trost, Alexandra Christodoulou, Amanda Christie, David M. Weinstock, Sophia Adamia, Richard Stone, Dharminder Chauhan, Kenneth C. Anderson, Hyuk-Soo Seo, Sirano Dhe-Paganon, Martin Sattler, Nathanael S. Gray, James D. Griffin*, Sara J. Buhrlage*. Inhibition of USP10 induces degradation of oncogenic FLT3. Nature Chemical Biology. 13 (12), 1207-1215. Oct. 2017 Jing Yang*, Ellen L. Weisberg. HSP70 and FLT3-ITD: targeting chaperone system to overcome drug resistance. (*Corresponding author) Blood Science. 3 (04), 151-153. Oct. 2021 Jing Yang#, Peng Xu#, Lei Han#, Zhixiang Guo, Xiuwen Wang, Zuojia Chen, Jia Nie, Shuying Yin, Miranda Piccioni, Andy Tsun, Ling Lv, Shenglin Ge and Bin Li. Cutting Edge: Ubiquitin-Specific Protease 4 Promotes Th17 Cell Function under Inflammation by Deubiquitinating and Stabilizing RORγt. The Journal of Immunology. Mar. 2015. pii: 1401451 Xiuwen Wang#, Jing Yang#, Lei Han, Kaixia Zhao, Qingsi Wu, Zhiyuan Li, Ling Lv and Bin Li. TRAF5 Mediated K63-linked Polyubiquitination Plays an Essential Role in the Positive regulation of RORγt on promoting IL-17A Expression. Journal of Biological Chemistry. October 2015. M115.664573 Lei Han#, Jing Yang#, Xiuwen Wang, Shuying Yin, Zhiyuan Li, Jing Zhang, Yue Xing, Zuojia Chen, Andy Tsun, Dan Li, Miranda Piccioni, Yu Zhang, Qiang Guo, Lindi Jiang, Liming Bao, Ling Lv and Bin Li. The E3 deubiquitinase USP17 is a positive regulator of retinoic acid-related orphan nuclear receptor γt (RORγt) in Th17 cells. Journal of Biological Chemistry. 2014 Sep. 12;289(37):25546-55